Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: A prospective with quality control 10-year follow-up study

被引:83
作者
Roukos, DH
Lorenz, M
Karakostas, K
Paraschou, P
Batsis, C
Kappas, AM
机构
[1] Goethe Univ Frankfurt, Dept Gen & Vasc Surg, D-60590 Frankfurt, Germany
[2] Univ Ioannina, Dept Surg, GR-45110 Ioannina, Greece
[3] Univ Ioannina, Dept Math, GR-45110 Ioannina, Greece
[4] Ioannina Univ Hosp, Dept Biopathol & Lab Med, Ioannina 45500, Greece
关键词
gastric cancer; extensive surgery; recurrence; survival; prognostic factors;
D O I
10.1054/bjoc.2001.1720
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
UICC classification accurately predicts overall survival brit not recurrence-risk. We report here data of overall and first site-specific recurrence following curative surgery useful for the development of recurrence-oriented preventive target therapies. Patients who underwent resection for gastric cancer were stratified according to curability of surgery [curative (R0) vs non-curative resection], extent of surgery [limited (D1) vs extended (D2) node dissection] and pathological nodal/serosal status. The intent-to-treat principle, log-rank test and Cox regression analysis were used for statistical analysis of time-to-event (recurrence, death) endpoints. Curative resection only produced a chance of cure whereas survival was very poor following non-curative-resection (P < 0.0001). For D2 R0 subgroup of patients, a pathological serosa and a node state-based classification into three groups, proved to be of clinical implication. Risk of recurrence after a median follow-up of 92 months was low among patients with both serosa and node-negative cancer (first group; 11%), moderate among those with either serosa or node-positive cancer (second group; 53%) and very high among those with both serosa and node-positive cancer (third group; 83%). in multivariate analysis. the relative risks of recurrence and death from gastric cancer among patients in the second and third groups, as compared to those in the first, were 7.07 (95% CI, 2.36-21.17; P = 0.0002) and 1.19 (95% CI, 5.76-45.54; P < 0.0001) respectively. First site-specific recurrence analysis revealed: low rate of loco-regional recurrence alone (12%), serosa state determinant factor of the site-recurrence (peritoneal for serosa-positive and haematogenous for serosa-negative cancers) and dramatic increase of all types of recurrence by the presence of nodal metastases. Our findings demonstrate that a pathological serosa- and node-based classification is very simple and predicts accurately site-specific recurrence-risks. Furthermore they reveal that risk of recurrence following curative D2 surgery alone is law for serosa- and node-negative cancers, but very high in serosa- and node-positive cancers suggesting the need for new therapeutic strategies in this subgroup of patients. (C) 2001 Cancer Research Campaign.
引用
收藏
页码:1602 / 1609
页数:8
相关论文
共 26 条
[1]
[Anonymous], 2000, LANCET, V355, P157
[2]
Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer [J].
Averbach, AM ;
Jacquet, P .
BRITISH JOURNAL OF SURGERY, 1996, 83 (06) :726-733
[3]
BEARHS OH, 1992, MANUAL STAGING
[4]
Extended lymph-node dissection for gastric cancer [J].
Bonenkamp, JJ ;
Hermans, J ;
Sasako, M ;
van de Velde, CJH .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (12) :908-914
[5]
Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. [J].
Braun, S ;
Pantel, K ;
Muller, P ;
Janni, W ;
Hepp, F ;
Kentenich, CRM ;
Gastroph, S ;
Wischnik, A ;
Dimpfl, T ;
Kindermann, G ;
Riethmuller, G ;
Schlimok, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) :525-533
[6]
Lymph-node dissection for gastric cancer [J].
Brennan, MF .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (12) :956-958
[7]
SURGICAL PATHOLOGICAL-STAGE MIGRATION CONFOUNDS COMPARISONS OF GASTRIC-CANCER SURVIVAL RATES BETWEEN JAPAN AND WESTERN COUNTRIES [J].
BUNT, AMG ;
HERMANS, J ;
SMIT, VTHBM ;
VANDEVELDE, CJH ;
FLEUREN, GJ ;
BRUIJN, JA .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :19-25
[8]
COX DR, 1972, J R STAT SOC B, V34, P187
[9]
Patient survival after D1 and D2 resections for gastric cancer:: long-term results of the MRC randomized surgical trial [J].
Cuschieri, A ;
Weeden, S ;
Fielding, J ;
Bancewicz, J ;
Craven, J ;
Joypaul, V ;
Sydes, M ;
Fayers, P .
BRITISH JOURNAL OF CANCER, 1999, 79 (9-10) :1522-1530
[10]
State of the art in the treatment of gastric cancer: from the 71st Japanese Gastric Cancer Congress [J].
Masashi Fujii ;
Juei Sasaki ;
Toshifusa Nakajima .
Gastric Cancer, 1999, 2 (3) :151-157